Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes
Authors:
- Trevor J BledsoeTBTrevor J Bledsoe
- Anisha R NobleANAnisha R Noble
- Grant K HunterGHGrant K Hunter
- Lisa A RybickiLRLisa A Rybicki
- Aaron HoscharAHAaron Hoschar
- Deborah J ChuteDCDeborah J Chute
- Jerrold P SaxtonJSJerrold P Saxton
- John F GreskovichJGJohn F Greskovich
- David J AdelsteinDADavid J Adelstein
- Shlomo A KoyfmanSKShlomo A Koyfman
Open Access
- 9 July 2013
- journal article
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 174
Abstract
Background: Tumor human papillomavirus (HPV) status has emerged as one of the most powerful prognostic factors for disease control and survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). We reviewed our experience in patients with OPSCC and known tumor HPV status treated with definitive chemoradiotherapy (CRT). Methods: Patients with stage III-IVb OPSCC and known tumor HPV status treated with CRT between 2006 and 2011 were identified from an IRB approved registry for this retrospective review. Outcomes were estimated using the Kaplan-Meier method and compared between HPV-positive and negative patients using the log-rank test. Results: Of the 121 pts (89% male, 93% Caucasian) included in this study, median age was 57 (range: 40–73) and median follow-up was 21 months (range: 6–63). Ninety-seven (80%) patients were HPV-positive and 24 (20%) were HPV-negative. Primary site was base of tongue (55%), tonsil (44%), and oropharyngeal wall (2%). Two year rates of locoregional recurrence (3% vs. 26%; p = 0.002), disease free survival (93% vs. 64%; p = 0.001) and overall survival (94% vs 73%; p = 0.002) were superior in HPV-positive patients, while rates of distant recurrence were similar (3% vs. 5%; p = 0.98). While acute toxicities were similar between both groups, patients with HPV-positive disease were more likely to resume a normal diet (90% vs. 65%; p = 0.017) at last follow up. Also, no HPV-positive patient required a feeding tube beyond 6 months after treatment, compared with 24% of HPV-negative patients. Conclusions: Definitive CRT produces excellent rates of disease control with minimal late toxicity for patients with HPV-positive OPSCC. Studies of OPSCC should account for tumor HPV status when identifying factors prognostic for outcome.Keywords
This publication has 19 references indexed in Scilit:
- The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Cancer: A Review of the LiteratureISRN Oncology, 2012
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- Low-lying Cervical Metastases Predict for Distant Metastasis in N2 Oropharyngeal Cancer Patients Treated with Intensity Modulated RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialJournal of Clinical Oncology, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG AnalysisJournal of Clinical Oncology, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysisInternational Journal of Cancer, 2007
- Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2006